Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression

Bortezomib (Velcal) was the first proteasome inhibitor to be approved by the US Food and Drug Administration to treat patients with relapsed/refractory multiple myelomas. Previous studies have demonstrated that bortezomib inhibits tumor cell proliferation and induces apoptosis by blocking the nuclea...

Descripción completa

Detalles Bibliográficos
Autores principales: Suk, Fat-Moon, Lin, Shyr-Yi, Lin, Ren-Jye, Hsine, Yung-Hsin, Liao, Yen-Ju, Fang, Sheng-Uei, Liang, Yu-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694880/
https://www.ncbi.nlm.nih.gov/pubmed/26317903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694880/
https://www.ncbi.nlm.nih.gov/pubmed/26317903

Ejemplares similares